Tags

Type your tag names separated by a space and hit enter

Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.
AAPS PharmSciTech. 2020 Apr 15; 21(3):115.AP

Abstract

The objective of the current study was to develop ziprasidone hydrochloride monohydrate (ZHM) nanocrystal-based orally dispersible tablet (ODT) formulations. Design of experiment approach was used to develop ODTs. The tablets were compressed using direct compression method and characterized with quality control tests. In vitro dissolution studies and Caco-2 cell permeability tests were executed. The hardness and friability values of nanocrystal-based ODTs were found 31.2 N and 1.05%, respectively. The disintegration time was below 10 s. Dissolution profile in pH 7.4 phosphate buffer showed that nanocrystal-based ODTs and commercial product were dissolved in 120 min 58.98% and 16%, respectively. In pH 7.4 phosphate buffer with SLS, sample groups dissolved above 85% at the end of the study. Permeability value and cumulative ZHM amount on the cells were improved with nanocrystals. In conclusion, the novel formulation of ZHM nanocrystal-based ODTs was successfully developed for alternative dosage form.

Authors+Show Affiliations

Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Ankara, Turkey. Zoleant Pharmaceuticals International, Istanbul, Turkey.Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Ankara, Turkey.Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Ankara, Turkey. ncelebi51@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32296987

Citation

Tashan, Emine, et al. "Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization By Using Design of Experiment and in Vitro Evaluation." AAPS PharmSciTech, vol. 21, no. 3, 2020, p. 115.
Tashan E, Karakucuk A, Celebi N. Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AAPS PharmSciTech. 2020;21(3):115.
Tashan, E., Karakucuk, A., & Celebi, N. (2020). Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AAPS PharmSciTech, 21(3), 115. https://doi.org/10.1208/s12249-020-01653-9
Tashan E, Karakucuk A, Celebi N. Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization By Using Design of Experiment and in Vitro Evaluation. AAPS PharmSciTech. 2020 Apr 15;21(3):115. PubMed PMID: 32296987.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AU - Tashan,Emine, AU - Karakucuk,Alptug, AU - Celebi,Nevin, Y1 - 2020/04/15/ PY - 2019/11/25/received PY - 2020/03/07/accepted PY - 2020/4/17/entrez PY - 2020/4/17/pubmed PY - 2020/4/17/medline KW - dissolution KW - factorial design KW - nanocrystal(s) KW - oral drug delivery KW - physical characterization SP - 115 EP - 115 JF - AAPS PharmSciTech JO - AAPS PharmSciTech VL - 21 IS - 3 N2 - The objective of the current study was to develop ziprasidone hydrochloride monohydrate (ZHM) nanocrystal-based orally dispersible tablet (ODT) formulations. Design of experiment approach was used to develop ODTs. The tablets were compressed using direct compression method and characterized with quality control tests. In vitro dissolution studies and Caco-2 cell permeability tests were executed. The hardness and friability values of nanocrystal-based ODTs were found 31.2 N and 1.05%, respectively. The disintegration time was below 10 s. Dissolution profile in pH 7.4 phosphate buffer showed that nanocrystal-based ODTs and commercial product were dissolved in 120 min 58.98% and 16%, respectively. In pH 7.4 phosphate buffer with SLS, sample groups dissolved above 85% at the end of the study. Permeability value and cumulative ZHM amount on the cells were improved with nanocrystals. In conclusion, the novel formulation of ZHM nanocrystal-based ODTs was successfully developed for alternative dosage form. SN - 1530-9932 UR - https://www.unboundmedicine.com/medline/citation/32296987/Development_of_Nanocrystal_Ziprasidone_Orally_Disintegrating_Tablets:_Optimization_by_Using_Design_of_Experiment_and_In_Vitro_Evaluation L2 - https://dx.doi.org/10.1208/s12249-020-01653-9 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.